Emtricitabine/tenofovir disoproxil fumarate vs Ulonivirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Emtricitabine/tenofovir disoproxil fumarate · Truvada
Marketed by Gilead Sciences
NCT00323544 · Phase 3 · completed
This was a randomized, open-label, active-controlled trial of 220 participants, comparing Truvada with Combivir. Its primary endpoint was a laboratory measure—change in hemoglobin—not a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT07584122 (registry estimate)
Reported efficacy
The primary endpoint for the study is a change from baseline in absolute haemoglobin at Week 24.: Primary endpoint, week 24 change from baseline in absolute hemoglobin: switching to Truvada+efavirenz vs continuing Combivir+efavirenz, mean difference +0.37 g/dL (95% CI 0.15 to 0.58 g/dL), P<0.001, favoring the switch arm. (met)
Result source: NCT00323544
Ulonivirine
Developed by Merck & Co.
NCT04564547 · Phase 2 · completed
Randomized, triple-masked phase 2b switch study of once-weekly islatravir plus ulonivirine in virologically suppressed HIV-1 infection (161 participants). All three primary endpoints are adverse-event rates reported descriptively; no efficacy comparison was posted as primary. Its registered primary outcome on ClinicalTrials.gov is "Percentage of Participants Who Experienced One or More Adverse Events (AEs) During the Double-Blind Treatment Period +42 Days Post-Blind" (with 2 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: August 2027 · NCT06891066 (registry estimate)
Reported efficacy
Percentage of Participants Who Experienced One or More Adverse Events (AEs) During the Double-Blind Treatment Period +42 Days Post-Blind (Up to approximately 9 months); Percentage of Participants Who Discontinued Study Intervention Due to an AE During the Double-Blind Treatment Period (Up to approximately 8 months); Percentage of Participants Who Experienced One or More AEs During the Unblinded Safety Monitoring Period (Up to approximately 37 months): Percentage of Participants Who Experienced One or More Adverse Events (AEs) During the Double-Blind Treatment Period +42 Days Post-Blind (Up to approximately 9 months): Group 1: ISL 20 mg + Ulonivirine 100 mg 75 Percentage of Participants | Group 2: ISL 20 mg + Ulonivirine 200 mg 75.6 Percentage of Participants | Group 3: ISL 20 mg + Ulonivirine 400 mg 80 Percentage of Participants | Group 4: BIC/FTC/TAF 67.5 Percentage of Participants (not_applicable)
Result source: NCT04564547
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Emtricitabine/tenofovir disoproxil fumarate | Ulonivirine |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 83.8% vs 79.9%vs Daurunavir + RitonavirNCT022757805 other results
| —Trial running · NCT07266831 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not posted · NCT00323544 | —Trial running · NCT07266831 |
| CD4 count, change (week 48) | 224.1 vs 206.7vs Daurunavir + RitonavirNCT0227578012 other results
| —Trial running · NCT07266831 |
HIV-1 RNA below 50 copies/mL (week 48)
- Emtricitabine/tenofovir disoproxil fumarate
- 83.8% vs 79.9%vs Daurunavir + RitonavirNCT02275780
5 other results
- 85.2% vs 87.4% NCT01108510
- 73.1% vs 66% NCT02275780
- 72.1% vs 74.1% NCT01108510
- 77.9% vs 79.3% NCT01108510
- 71.6% vs 79.7% NCT01108510
- Ulonivirine
- —Trial running · NCT07266831
HIV-1 RNA 50 copies/mL or more (week 48)
- Emtricitabine/tenofovir disoproxil fumarate
- —Not posted · NCT00323544
- Ulonivirine
- —Trial running · NCT07266831
CD4 count, change (week 48)
- Emtricitabine/tenofovir disoproxil fumarate
- 224.1 vs 206.7vs Daurunavir + RitonavirNCT02275780
12 other results
- 192.7 vs 185.6 NCT02275780
- 310 vs 332 NCT01108510
- 277 vs 287 NCT01108510
- 291 vs 256 NCT00089505
- 223 vs 256 NCT00089505
- 213 vs 219 NCT01108510
- 172 vs 172 NCT00089505
- 350 vs 343 NCT01108510
- 191 vs 172 NCT00089505
- 158 vs 146 NCT01380080
- 96 vs 102 NCT01380080
- 8 vs 34 NCT00724711
- Ulonivirine
- —Trial running · NCT07266831
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Emtricitabine/tenofovir disoproxil fumarate: 4 of 4 rows · Ulonivirine: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Emtricitabine/tenofovir disoproxil fumarate | Ulonivirine |
|---|---|---|
| Dropout rate | 24.7%a NCT00458393 · Phase 3 show 15 more results16%Rectal Gel Lubricant + Truvada NCT02401230 · Phase 4 · registry result, not featured evidence · combination 24%Truvada NCT02401230 · Phase 4 · registry result, not featured evidence 20% NCT01380080 · Phase 4 · registry result, not featured evidence — NCT00724711 · Phase 4 · registry result, not featured evidence · combination 0%200/300 mg, Daily, by Mouth NCT00960622 · Phase 4 · registry result, not featured evidence —Truvada NCT00960622 · Phase 4 · registry result, not featured evidence — NCT00323492 · Phase 4 · registry result, not featured evidence 24.2%100 mg NCT02275780 · Phase 3 · registry result, not featured evidence —1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 79.9% NCT01108510 · Phase 3 · registry result, not featured evidence · combination 25% NCT01195467 · Phase 3 · registry result, not featured evidence 19.5% NCT00625404 · Phase 3 · registry result, not featured evidence 25.5%400 mg b.i.d. NCT00369941 · Phase 3 · registry result, not featured evidence 7.4%NVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence 8.4%NoNVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence | 5%400 mg weeklya NCT04564547 · Phase 2 · combination show 8 more results—400 mg weekly NCT04564547 · Phase 2 · combination —400 mg weekly NCT04564547 · Phase 2 · combination 4.9%200 mg weekly NCT04564547 · Phase 2 · combination —200 mg weekly NCT04564547 · Phase 2 · combination —200 mg weekly NCT04564547 · Phase 2 · combination 7.5%100 mg weekly NCT04564547 · Phase 2 · combination —100 mg weekly NCT04564547 · Phase 2 · combination —100 mg weekly NCT04564547 · Phase 2 · combination |
| Discontinued due to AEs | —a NCT00458393 · Phase 3 show 15 more results0%Rectal Gel Lubricant + Truvada NCT02401230 · Phase 4 · registry result, not featured evidence · combination 8%Truvada NCT02401230 · Phase 4 · registry result, not featured evidence — NCT01380080 · Phase 4 · registry result, not featured evidence — NCT00724711 · Phase 4 · registry result, not featured evidence · combination —200/300 mg, Daily, by Mouth NCT00960622 · Phase 4 · registry result, not featured evidence —Truvada NCT00960622 · Phase 4 · registry result, not featured evidence — NCT00323492 · Phase 4 · registry result, not featured evidence 1.6%100 mg NCT02275780 · Phase 3 · registry result, not featured evidence —1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 7.4% NCT01108510 · Phase 3 · registry result, not featured evidence · combination — NCT01195467 · Phase 3 · registry result, not featured evidence — NCT00625404 · Phase 3 · registry result, not featured evidence 5%400 mg b.i.d. NCT00369941 · Phase 3 · registry result, not featured evidence —NVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence —NoNVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence | —400 mg weeklya NCT04564547 · Phase 2 · combination show 8 more results—400 mg weekly NCT04564547 · Phase 2 · combination —400 mg weekly NCT04564547 · Phase 2 · combination —200 mg weekly NCT04564547 · Phase 2 · combination —200 mg weekly NCT04564547 · Phase 2 · combination —200 mg weekly NCT04564547 · Phase 2 · combination —100 mg weekly NCT04564547 · Phase 2 · combination —100 mg weekly NCT04564547 · Phase 2 · combination —100 mg weekly NCT04564547 · Phase 2 · combination |
| Serious AEs | 7.5%a NCT00458393 · Phase 3 show 15 more results0%Rectal Gel Lubricant + Truvada NCT02401230 · Phase 4 · registry result, not featured evidence · combination 0%Truvada NCT02401230 · Phase 4 · registry result, not featured evidence 20% NCT01380080 · Phase 4 · registry result, not featured evidence 7.7% NCT00724711 · Phase 4 · registry result, not featured evidence · combination —200/300 mg, Daily, by Mouth NCT00960622 · Phase 4 · registry result, not featured evidence 0%Truvada NCT00960622 · Phase 4 · registry result, not featured evidence 9.7% NCT00323492 · Phase 4 · registry result, not featured evidence 11.7%100 mg NCT02275780 · Phase 3 · registry result, not featured evidence 9.6%1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 18.6% NCT01108510 · Phase 3 · registry result, not featured evidence · combination 10% NCT01195467 · Phase 3 · registry result, not featured evidence 3.2% NCT00625404 · Phase 3 · registry result, not featured evidence 20.3%400 mg b.i.d. NCT00369941 · Phase 3 · registry result, not featured evidence 7.4%NVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence 10.4%NoNVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence | —400 mg weeklya NCT04564547 · Phase 2 · combination show 8 more results2.5%400 mg weekly NCT04564547 · Phase 2 · combination 2.7%400 mg weekly NCT04564547 · Phase 2 · combination —200 mg weekly NCT04564547 · Phase 2 · combination 7.3%200 mg weekly NCT04564547 · Phase 2 · combination 0%200 mg weekly NCT04564547 · Phase 2 · combination —100 mg weekly NCT04564547 · Phase 2 · combination 5%100 mg weekly NCT04564547 · Phase 2 · combination 0%100 mg weekly NCT04564547 · Phase 2 · combination |
| Most frequent reported AEs | a pharyngitis 20.2% (placebo 22.9%) parasitic infection intestinal 18.8% (placebo 17.6%) alanine aminotransferase increased 12.3% (placebo 12.6%) NCT00458393 · Phase 3 show 13 more resultserectile dysfunction 4.8% gastroenteritis 4.8% headache 4.8% NCT02401230 · Phase 4 · registry result, not featured evidence · combination gastroenteritis 5.3% pulmonary embolism 5.3% anxiety 0% NCT02401230 · Phase 4 · registry result, not featured evidence neutrophil count decreased 38% blood albumin decreased 35.6% blood sodium decreased 34% NCT01380080 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 9% diarrhea 8.4% cough 5.2% NCT00724711 · Phase 4 · registry result, not featured evidence · combination diarrhoea 9.7% abdominal pain 4.2% bronchitis 4.2% NCT00323492 · Phase 4 · registry result, not featured evidence 100 mg diarrhoea 18.8% upper respiratory tract infection 16.7% headache 16.4% NCT02275780 · Phase 3 · registry result, not featured evidence 1200 mg QD + Truvada headache 15.8% nausea 13.6% diarrhoea 13.4% NCT02131233 · Phase 3 · registry result, not featured evidence · combination diarrhoea 22.1% jaundice 22.1% ocular icterus 20.1% NCT01108510 · Phase 3 · registry result, not featured evidence · combination bilateral arm pain 2.5% cellulitis 2.5% diarrhoea 2.5% NCT01195467 · Phase 3 · registry result, not featured evidence blood phosphorus decreased 19.4% (placebo 18.3%) aspartate aminotransferase increased 13.1% (placebo 11.5%) headache 13.1% (placebo 14.3%) NCT00625404 · Phase 3 · registry result, not featured evidence 400 mg b.i.d. nasopharyngitis 26.7% headache 26% diarrhoea 25.6% NCT00369941 · Phase 3 · registry result, not featured evidence cough 23.1% neutrophil count decreased 23.1% rash 23.1% NCT00089505 · Phase 3 · registry result, not featured evidence neutrophil count decreased 27.3% rash 26.5% cough 24.1% NCT00089505 · Phase 3 · registry result, not featured evidence | show 5 more results |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Emtricitabine/tenofovir disoproxil fumarate
show 1 more result
show 3 more results
show 3 more results
show 13 more results
show 1 more result
show 5 more results
+ 14 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Emtricitabine/tenofovir disoproxil fumarate's landscape · Ulonivirine's landscape